1 / 19

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer. Andrea Wahner Hendrickson M.D. March 8, 2018. MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer. How do PARP inhibitors work? Why do they work better for some ovarian cancer over others?

liam
Download Presentation

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MOCA Living Well:Understanding PARP Inhibitors in Ovarian Cancer Andrea Wahner Hendrickson M.D. March 8, 2018

  2. MOCA Living Well:Understanding PARP Inhibitors in Ovarian Cancer • How do PARP inhibitors work? • Why do they work better for some ovarian cancer over others? • How can these drugs be used? • What is the difference between maintenance and treatment? • What are some common side effects? • How can I know if these drugs are an option for me?

  3. How do PARP inhibitors work?

  4. Why do they work better in some tumors? • Depends on genetics • BRCA1/ BRCA2 mutations • These mutations lead to difficulty in repairing DNA damage • PARP inhibitors enhance that difficulty • Can be a germline (inherited) mutation OR a somatic (tumor only) mutation • Other changes in DNA repair • Some of these can be analyzed by tumor tests • Discuss with your physician

  5. FDA Approved PARP Inhibitors

  6. What is the difference between maintenance therapy and treatment? • Treatment • An initial treatment used in attempt to shrink the current tumor • Example: Carboplatin and Doxil for ovarian cancer that has come back • Maintenance therapy • Continuing to treat after completion of standard round of chemotherapy • Used to avoid or slow the cancer’s return • Slow the growth of advanced cancer after the initial treatment

  7. Risk/Benefits of Maintenance Therapy • Benefits • May help keep cancer from coming back • May slow down cancer growth • Disadvantages • Side effects • Treatment cost • More doctor visits • Limited information on long term side effects and benefits for each individual

  8. A few words on each of the three agents

  9. LynparzaFDA Approved Indications • Maintenance therapy • Recurrent (not after first chemotherapy) • Tumor has completely or partially “responded” to the second platinum chemotherapy • All women regardless of mutations • Treatment • Germline (inherited) BRCA mutated ovarian cancer who have been treated with 3 or more prior lines of therapy

  10. LynparzaMost common side effects • Nausea • Fatigue • Low red blood cell count • Vomiting • Diarrhea • Low neutrophil count

  11. RubracaFDA Approved Indications • Treatment • BRCA mutation (germline (inherited) OR tumor only) • FoundationFocus CDxBRCA test • 2 or more prior therapies • Maintenance therapy • Under FDA review

  12. RubracaMost common side effects • Nausea • Fatigue (including weakness) • Vomiting • Low red blood cell count • Abdominal pain • Changes in taste

  13. ZejulaFDA Approved Indications • Maintenance therapy • Recurrent (not after first chemotherapy) • Tumor has partially or completely “responded” to the most recent platinum chemotherapy • All women regardless of mutations • Treatment • Currently under review

  14. ZejulaMost common side effects • Nausea • Low platelet count • Fatigue • Low red blood cell count • Vomiting • Low neutrophil count

  15. PARP Inhibitor Side Effects • All have a similar side effects, but some are more common and/or more severe in one versus another • All can cause AML/MDS (blood diseases) • Talk to your physician as to which may work best for you • Individuals react differently • No one right answer for everyone

  16. Summary of the PARP Inhibitors

  17. What is companion testing? • Test used with a drug to determine its applicability to a specific person • Often co-developed with the drug to help select or exclude patient groups for treatment • Used in the “treatment” setting • Not required in the “maintenance” setting

  18. What is the benefit of PARPi maintenance? • Depends on your genetic make-up and the genetic make-up of the tumor • Most improvement seen with BRCA mutation • Least improvement (but improvement still seen) in those without any mutations or features of high DNA damage

  19. Parting thoughts. . .PARP Inhibitors • 3 FDA approved drugs • Can be used as treatment or maintenance • Which to use is based on specific indication and discussion with your physician • Genetic status • Side effects • Dosing schedule

More Related